Overview
Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.
Background
Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.
Indication
Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.
Associated Conditions
- Acute Pain
- Premature Ejaculation
- Severe Pain
- Acute, moderate, severe Pain
- Moderate Pain
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/06/29 | Not Applicable | Completed | Syed Muhammad Abbas | ||
2025/02/05 | N/A | Recruiting | |||
2024/12/19 | Phase 4 | Active, not recruiting | medina medical center | ||
2024/12/11 | Not Applicable | Not yet recruiting | |||
2024/12/09 | Phase 3 | Recruiting | |||
2024/09/25 | Phase 4 | Not yet recruiting | |||
2024/09/19 | Phase 4 | Completed | Istanbul University - Cerrahpasa (IUC) | ||
2024/08/20 | Early Phase 1 | ENROLLING_BY_INVITATION | |||
2024/04/26 | Phase 2 | Completed | Asbjørn Mohr Drewes | ||
2024/04/18 | Phase 4 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Aidarex Pharmaceuticals LLC | 33261-483 | ORAL | 50 mg in 1 1 | 10/5/2012 | |
Aidarex Pharmaceuticals LLC | 33261-105 | ORAL | 50 mg in 1 1 | 10/22/2014 | |
NuCare Pharmaceuticals,Inc. | 68071-2648 | ORAL | 100 mg in 1 1 | 2/25/2022 | |
Medsource Pharmaceuticals | 45865-357 | ORAL | 50 mg in 1 1 | 7/19/2015 | |
Medsource Pharmaceuticals | 45865-170 | ORAL | 37.5 mg in 1 1 | 3/5/2024 | |
Lupin Pharmaceuticals, Inc. | 68180-697 | ORAL | 100 mg in 1 1 | 1/16/2024 | |
Galephar Pharmaceutical Research Inc. | 66277-239 | ORAL | 100 mg in 1 1 | 12/19/2022 | |
Quality Care Products, LLC | 55700-996 | ORAL | 100 mg in 1 1 | 2/24/2023 | |
Sun Pharmaceutical Industries, Inc. | 47335-860 | ORAL | 200 mg in 1 1 | 12/12/2023 | |
Palmetto Pharmaceuticals, Inc. | 68134-402 | ORAL | 5 mg in 1 mL | 12/21/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
SKUDEXA FILM-COATED TABLET 75 MG/25 MG | SIN15394P | TABLET, FILM COATED | 75 mg | 12/13/2017 | |
PENGESIC CAPSULE 50 mg | SIN10512P | CAPSULE | 50.00 mg | 12/8/1998 | |
ACUGESIC INJECTION 50 mg/ml (without preservative) | SIN10045P | INJECTION | 50 mg/ml | 9/23/1998 | |
MABRON INJECTION 100 mg/2 ml | SIN08740P | INJECTION | 100 mg/2 ml | 6/6/1996 | |
ULTRADOL F.C. TABLETS 37.5MG/325MG | SIN16498P | TABLET, FILM COATED | 37.5mg | 5/19/2022 | |
TRADOL INJECTION 50 mg/ml | SIN10057P | INJECTION | 50 mg/ml | 9/23/1998 | |
ACUGESIC CAPSULE 50 mg | SIN08953P | CAPSULE | 50 mg | 10/2/1996 | |
TRAMADOL STADA INJECTION 100 mg/2 ml | SIN08367P | INJECTION | 100 mg/2 ml | 10/2/1995 | |
TRACIDOL INJECTION 100mg/2ml | SIN15303P | INJECTION, SOLUTION | 100mg | 7/24/2017 | |
TRAMADOL 50 STADA CAPSULE 50 mg | SIN08365P | CAPSULE | 50 mg | 10/2/1995 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Tramadol Hydrochloride Capsules | 欧洲塞浦路斯麦道甘美大药厂 | H20140362 | 化学药品 | 胶囊剂 | 11/5/2019 |
Tramadol Hydrochloride Capsules | 国药准字H10950223 | 化学药品 | 胶囊剂 | 6/4/2020 | |
Tramadol Hydrochloride Capsules | 国药准字HJ20160417 | 化学药品 | 胶囊剂 | 7/5/2021 | |
Tramadol Hydrochloride Capsules | medochemie ltd. | 国药准字HJ20140362 | 化学药品 | 胶囊剂 | 4/15/2025 |
Tramadol Hydrochloride Suppositories | 国药准字H20000738 | 化学药品 | 栓剂 | 6/17/2020 | |
Tramadol Hydrochloride Injection | 国药准字HJ20140813 | 化学药品 | 注射剂 | 8/20/2024 | |
Tramadol Hydrochloride Injection | 国药准字HJ20140812 | 化学药品 | 注射剂 | 8/20/2024 | |
Tramadol Hydrochloride Injection | 国药准字H20023537 | 化学药品 | 注射剂 | 7/23/2020 | |
Tramadol Hydrochloride Injection | 国药准字H10960107 | 化学药品 | 注射剂 | 3/15/2024 | |
Tramadol Hydrochloride Injection | 国药准字H10910037 | 化学药品 | 注射剂 | 9/23/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
TRAMED CAPSULES 50MG | N/A | N/A | N/A | 3/12/2025 | |
MODSENAL CAPSULES 50MG | N/A | N/A | N/A | 5/12/2025 | |
TRAMADOL 50 STADA CAP 50MG | N/A | N/A | N/A | 1/14/1997 | |
TRAMADOL 100 STADA SUPPOSITORIES 100MG | N/A | N/A | N/A | 9/15/1999 | |
TRAMO CAP 50MG | N/A | N/A | N/A | 12/7/1994 | |
TRAMADOL HYDROCHLORIDE TABLETS USP 50MG | N/A | N/A | N/A | 2/17/2021 |